Literature DB >> 8781754

ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.

W Linz1, G Wiemer, H L Schmidts, W Ulmer, D Ruppert, B A Schölkens.   

Abstract

UNLABELLED: In male Sprague Dawley rats with left ventricular hypertrophy (LVH) and hypertension induced by aortic constriction (AC) and subsequent myocardial infarction (MI) by occlusion of the left coronary artery the effects of ACE inhibition with ramipril (RA 1 mg/kg/day via the drinking water during 6 weeks) on survival as well as cardiac function and metabolism were investigated. Respective groups (sham AC; AC; AC + sham MI; normotensive animals with sham MI; MI; MI + RA) served as comparisons. Following MI hypertensive rats with AC and LVH revealed an increased postoperative mortality (68%) when compared to normotensives without AC (28%). ACE inhibition with ramipril significantly reduced mortality in hypertensive rats by 26%. Untreated hypertensive animals with LVH clearly showed reduced MI size (6.2 +/- 2.3%) in comparison with untreated normotensive animals and MI (31.0 +/- 3.3%). In hypertensive rats with MI which died during the study a significant increase in infarct size was found compared to those which survived MI. In normotensive animals ramipril reduced infarct size by 50%. Due to the quite small infarct size observed in hypertensive rats, ACE inhibition did not further reduce MI in these animals. LVH as well as hydroxyproline/proline ratio was diminished by ACE inhibitor treatment. In the isolated hearts of ramipril treated rats contractility was improved when compared to the respective untreated groups with MI. In the coronary effluent of isolated hearts from rats with AC and MI lactate dehydrogenase and creatine kinase activities as well as lactate levels were increased. Ramipril treatment starting one week before MI normalized these parameters and in addition increased prostacyclin output. Hearts with MI from treated normotensive animals contained increased energy rich phosphates when compared to hearts from untreated rats with MI.
CONCLUSIONS: Hypertensive rats with LVH undergoing MI experience increased postoperative mortality probably due to a reduced tolerance to myocardial ischemia and occurrence of arrhythmias. In these animals ACE inhibition with ramipril increased survival. Both, increased survival in hypertensive and reduction in infarct size in normotensive rats by ACE inhibition with ramipril was accompanied by an improved myocardial metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781754     DOI: 10.3109/10641969609081775

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  5 in total

1.  Impaired cardiac ischemic tolerance in spontaneously hypertensive rats is attenuated by adaptation to chronic and acute stress.

Authors:  T Ravingerová; I Bernátová; J Matejíková; V Ledvényiová; M Nemčeková; O Pecháňová; N Tribulová; J Slezák
Journal:  Exp Clin Cardiol       Date:  2011

2.  Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure.

Authors:  Carla J Weinheimer; Ling Lai; Daniel P Kelly; Attila Kovacs
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-01       Impact factor: 2.557

Review 3.  Cardiac remodeling and physical training post myocardial infarction.

Authors:  Michael A Garza; Emily A Wason; John Q Zhang
Journal:  World J Cardiol       Date:  2015-02-26

4.  Small animal models of heart failure.

Authors:  Christian Riehle; Johann Bauersachs
Journal:  Cardiovasc Res       Date:  2019-11-01       Impact factor: 10.787

5.  Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry.

Authors:  Bing Hui Wang; Simone Reisman; Mark Bailey; Andrew Kompa; Mustafa Ayhan; Henry Krum; Gregory Rice
Journal:  Clin Transl Med       Date:  2012-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.